Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Background Immune-modulating antibodies targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have demonstrated promising antitumor efficacy in various types of cancers, especially highly mutated ones. Genetic alterations in DNA damage response and repair (DDR) genes can l...

Full description

Saved in:
Bibliographic Details
Main Authors: Jae Ho Byun, Jeeyun Lee, Kyong Hwa Park, Eun Joo Kang, Sang Joon Shin, In Gyu Hwang, Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Jason K Sa, Sook Ryun Park, Jung Sun Kim, Yu Jung Kim, Woo Kyun Bae, Won Jin Chang, Eun-Ok Kim
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/3/e008638.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/3/e008638.full

Similar Items